INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 424m ago
HOUSE PTR23m ago
SEC 13F23m ago
ROBINHOOD CHAIN23m ago
Public company

AIMAIM ImmunoTech Inc.

CIK 0000946644

EDGAR filingsOpen in network
Disclosed transactions2
Buys / sells2 / 0
Max Insider Score37
Connections3with evidence

AIM · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
33
EK
Equels Thomas KDirector, CEO & President
AIMAIM ImmunoTech Inc.
Open-market purchase
BUY$5,068
31.7K sh
Oct 23, 2026Oct 26, 2026
traded Oct 23, 2026
+3dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
  • ← Insider ofevidence
    Equels Thomas KDirector, CEO & President · Oct 23, 2026
  • ← Lobbied forevidence
    BUCHANAN INGERSOLL & ROONEY PCLDA Q2Y 2026 second quarter · issues not listed · Aug 26, 2026
37
EK
Equels Thomas KDirector, CEO & President
AIMAIM ImmunoTech Inc.
Open-market purchase
BUY
$5,094
31.3K sh
Oct 22, 2026
Oct 23, 2026
traded Oct 22, 2026
+1d
SEC FORM 4

Evidence

Lobbying

$0 reported · de-duplicated
2026 Q2 $0 via firms2026 Q1 $0 via firms
  • BUCHANAN INGERSOLL & ROONEY PC—2026 Q2 · posted Aug 26, 2026 ·
  • BUCHANAN INGERSOLL & ROONEY PC—2026 Q1 · posted Aug 26, 2026 ·

Connected PAC contributions

FEC · direct to members

No contributions from a PAC connected to this company.